Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA.
Vet Comp Oncol. 2010 Dec;8(4):273-82. doi: 10.1111/j.1476-5829.2010.00225.x.
Doxorubicin may cause a rare but serious cardiotoxicity. Dexrazoxane is a cardioprotectant drug used to reduce the risk of cardiotoxicity in human patients. In this study, 25 tumour-bearing dogs were treated with concurrent doxorubicin and dexrazoxane. The total number of doses of dexrazoxane given was 54 (range 1-5 doses per dog, median 2 doses). Five dogs received more than 165 mg m(2) cumulative doxorubicin dose before starting dexrazoxane. Haematologic, gastrointestinal and cardiovascular toxicities were considered tolerable. The combination of doxorubicin with dexrazoxane was well tolerated with minimal side-effects in this patient cohort. Future studies are required to evaluate potential cardioprotective effects of dexrazoxane given concurrently with doxorubicin.
多柔比星可能导致罕见但严重的心脏毒性。右雷佐生是一种心脏保护药物，用于降低人类患者发生心脏毒性的风险。在这项研究中，25 只荷瘤犬接受了多柔比星和右雷佐生的联合治疗。右雷佐生的总剂量为 54 剂（每只犬 1-5 剂，中位数为 2 剂）。5 只犬在开始使用右雷佐生前接受了超过 165mg/m²的累积多柔比星剂量。血液学、胃肠道和心血管毒性被认为是可耐受的。在该患者队列中，多柔比星联合右雷佐生耐受性良好，副作用最小。需要进一步的研究来评估多柔比星联合右雷佐生的潜在心脏保护作用。
